ReviewHematology/oncology clinics of North America2017
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.
Review in Hematology/oncology clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Treatment-refractory cutaneous Rosai-Dorfman disease responsive to oral methotrexate and topical trametinib.JAAD case reports · 2023Article
- Erdheim-Chester disease: A multisystem disease case illustration with rare manifestations and treatment challenges.Clinical case reports · 2023Article
- Solitary Involvement of the Liver: A Rare Manifestation of Langerhans Cell Histiocytosis.The American journal of case reports · 2022Article
- Potential role ofFrontiers in pediatrics · 2022Article
- Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling.Biomedicines · 2021Article
- Effective treatment of progressive nodular histiocytosis by intermediate-dose cytarabine: a case report and literature review.American journal of translational research · 2021Article
- Sclerosing epithelioid mesenchymal neoplasm of the pancreas - a proposed new entity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Review
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Histiocytic disorders represent clonal disorders of cells believed to be derived from the monocyte, macrophage, and/or dendritic cell lineage presenting with a range of manifestations. Although their nature as clonal versus inflammatory nonclonal conditions have long been debated, recent studies identified numerous somatic mutations that activate mitogen-activated protein kinase signaling in clinically and histologically diverse forms of histiocytosis. Clinical trials and case series have revealed that targeting aberrant kinase signaling using BRAF and/or MEK inhibitors may be effective. These findings suggest that a personalized approach in which patient-specific alterations are identified and targeted may be a critically important therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.